- While doing some speculative biotech window shopping, I came across VBL Therapeutics sitting on the sub-$100M market cap shelf. After a quick inspection, I am heading to the checkout.
- The company's lead candidate, VB-111, is moving closer to the finish line in platinum-resistant ovarian cancer. So far, VB-111 has shown to have at least a 58% response rate.
- I believe the VBLT's risk-reward profile favors a long position due to its potential upside and its current valuation.
- I discuss my leading downside risks and will reveal how I plan to initiate a position in VBLT.
For further details see:
VBL Therapeutics: A Speculative Play With An Enticing Risk-Reward Profile